| Medical and Health Sciences | 2021-2025 | 423 | US 144 | 99.91 |
| Reproductive Medicine | Lifetime | 19 | US 10 | 99.86 |
| Oncology | Lifetime | 320 | US 182 | 99.47 |
| Obstetrics and Gynecology | Lifetime | 102 | US 48 | 99.36 |
| Cancer Research | Lifetime | 955 | US 484 | 92.64 |
| Reproductive Medicine | 2021-2025 | 17 | US 4 | 99.68 |
| Oncology | 2021-2025 | 84 | US 35 | 99.46 |
| Obstetrics and Gynecology | 2021-2025 | 62 | US 21 | 98.60 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 888 | US 325 | 88.05 |
| Cancer Research | 2021-2025 | 401 | US 156 | 71.10 |
| Ovarian cancer diagnosis and treatment | Lifetime | 12 | US 6 | 99.86 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 5 | US 1 | 99.75 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 14 | US 7 | 99.80 |
| PARP inhibition in cancer therapy | Lifetime | 12 | US 6 | 99.62 |
| Cancer Mechanisms and Therapy | Lifetime | 44 | US 25 | 99.25 |
| Angiogenesis and VEGF in Cancer | Lifetime | 166 | US 87 | 98.84 |
| Colorectal and Anal Carcinomas | Lifetime | 274 | US 113 | 98.08 |
| Renal cell carcinoma treatment | Lifetime | 393 | US 223 | 98.23 |
| Cancer, Lipids, and Metabolism | Lifetime | 479 | US 238 | 98.18 |
| BRCA gene mutations in cancer | Lifetime | 324 | US 177 | 97.68 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 401 | US 233 | 96.90 |
| Endometriosis Research and Treatment | Lifetime | 542 | US 167 | 97.24 |
| Cervical Cancer and HPV Research | Lifetime | 733 | US 319 | 96.96 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 512 | US 261 | 95.88 |
| Uterine Myomas and Treatments | Lifetime | 477 | US 162 | 97.01 |
| Economic and Financial Impacts of Cancer | Lifetime | 513 | US 325 | 94.99 |
| Multiple and Secondary Primary Cancers | Lifetime | 692 | US 292 | 93.71 |
| Gestational Trophoblastic Disease Studies | Lifetime | 837 | US 298 | 80.68 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 11 | US 3 | 99.79 |
| PARP inhibition in cancer therapy | 2021-2025 | 14 | US 6 | 99.53 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 39 | US 9 | 99.18 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 11 | US 2 | 95.75 |
| BRCA gene mutations in cancer | 2021-2025 | 48 | US 24 | 97.82 |
| Estrogen and related hormone effects | 2021-2025 | 131 | US 59 | 91.45 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 937 | US 295 | 94.42 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 269 | US 174 | 92.48 |
| HER2/EGFR in Cancer Research | 2021-2025 | 385 | US 140 | 93.61 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 786 | US 331 | 93.50 |
| Cancer Mechanisms and Therapy | 2021-2025 | 270 | US 39 | 86.73 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 131 | US 31 | 84.85 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 394 | US 95 | 84.10 |
| Colorectal and Anal Carcinomas | 2021-2025 | 967 | US 231 | 81.94 |
| Chromatin Remodeling and Cancer | 2021-2025 | 417 | US 176 | 69.31 |
| 14-3-3 protein interactions | 2021-2025 | 149 | US 38 | 50.58 |
